{"id":72188,"date":"2026-08-10T13:41:28","date_gmt":"2026-08-10T05:41:28","guid":{"rendered":"https:\/\/flcube.com\/?p=72188"},"modified":"2026-08-10T13:41:29","modified_gmt":"2026-08-10T05:41:29","slug":"hopstem-biotech-completes-first-close-of-nearly-rmb-200-million-series-c-to-advance-ipsc-cell-therapy-pipeline-led-by-hnpc01","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72188","title":{"rendered":"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hopstem Biotechnology<\/strong> announced the completion of the <strong>first close<\/strong> of its <strong>nearly RMB 200 million Series C financing round<\/strong>. The round was participated in by new shareholders <strong>Tasly Capital<\/strong>, <strong>HBVC<\/strong>, and <strong>Guangzhou Health Investment<\/strong>, along with existing shareholder <strong>Longmen Capital<\/strong>. The proceeds will be used to <strong>accelerate the company&#8217;s clinical development across multiple indications<\/strong> and to <strong>prepare for commercial\u2011scale production<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financing-overview\" class=\"wp-block-heading\">Financing Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hopstem Biotech<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series C (first close completed)<\/td><\/tr><tr><td><strong>Size<\/strong><\/td><td>Nearly RMB 200 million<\/td><\/tr><tr><td><strong>New Investors<\/strong><\/td><td>Tasly Capital, HBVC, Guangzhou Health Investment<\/td><\/tr><tr><td><strong>Existing Investor<\/strong><\/td><td>Longmen Capital<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Accelerate clinical development across multiple indications; prepare for commercial\u2011scale production<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-profile-amp-technology-platform\" class=\"wp-block-heading\">Company Profile &amp; Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> January 2017 \u2014 a global innovative biotechnology company dedicated to developing <strong>iPSC\u2011derived off\u2011the\u2011shelf cell therapy products<\/strong><\/li>\n\n\n\n<li><strong>Core IP:<\/strong> Leading global patents and technological advantages in <strong>iPSC reprogramming<\/strong>, <strong>pluripotent stem cell neural differentiation<\/strong>, and various <strong>cell engineering<\/strong> approaches<\/li>\n\n\n\n<li><strong>Manufacturing &amp; Analytics:<\/strong><\/li>\n\n\n\n<li>Established an <strong>iPSC cell product CMC platform<\/strong><\/li>\n\n\n\n<li><strong>Closed automated production processes<\/strong><\/li>\n\n\n\n<li>Multiple innovative analytical methods<\/li>\n\n\n\n<li><strong>Licensing Assets:<\/strong> <strong>GMP\u2011grade iPSC cell lines<\/strong> available for commercial licensing both domestically and internationally, alongside a multi\u2011asset product pipeline<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-lead-asset-hnpc01\" class=\"wp-block-heading\">Lead Asset: hNPC01<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>hNPC01 (human forebrain neural progenitor cells)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Earliest iPSC cell product of its kind to receive both <strong>CDE<\/strong> and <strong>FDA IND approvals<\/strong> in China, with the fastest development progress<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase 1 clinical trials completed<\/td><\/tr><tr><td><strong>Designations<\/strong><\/td><td><strong>FDA Fast Track designation<\/strong>; <strong>Regenerative Medicine Advanced Therapy (RMAT)<\/strong> certification<\/td><\/tr><tr><td><strong>Target Conditions<\/strong><\/td><td>Stroke, traumatic brain injury sequelae, cerebral palsy, epilepsy, and other conditions with major unmet medical needs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investor Validation:<\/strong> Participation from three new institutional investors alongside an existing shareholder signals continued confidence in Hopstem&#8217;s iPSC platform at a time when cell therapy funding has grown more selective.<\/li>\n\n\n\n<li><strong>Off\u2011the\u2011Shelf Positioning:<\/strong> Allogeneic, iPSC\u2011derived cell therapies aim to overcome the cost and scalability constraints of autologous products, and Hopstem&#8217;s closed automated manufacturing and CMC capabilities are central to that thesis.<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> hNPC01&#8217;s dual CDE\/FDA IND status, completed Phase 1 program, and both Fast Track and RMAT designations position it among the most clinically advanced iPSC\u2011derived neural cell products globally.<\/li>\n\n\n\n<li><strong>Dual Revenue Pathways:<\/strong> Beyond the clinical pipeline, commercial licensing of GMP\u2011grade iPSC cell lines offers a near\u2011term monetization channel domestically and internationally, while the Series C proceeds fund the push toward commercial\u2011scale production.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Hopstem Biotech&#8217;s financing, clinical development of hNPC01, and commercialization preparations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and manufacturing scale\u2011up.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[77,20,1618],"class_list":["post-72188","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-finance","tag-hopstem-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million Series C financing round. The round was participated in by new shareholders Tasly Capital, HBVC, and Guangzhou Health Investment, along with existing shareholder Longmen Capital. The proceeds will be used to accelerate the company&#039;s clinical development across multiple indications and to prepare for commercial\u2011scale production.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72188\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01\" \/>\n<meta property=\"og:description\" content=\"Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million Series C financing round. The round was participated in by new shareholders Tasly Capital, HBVC, and Guangzhou Health Investment, along with existing shareholder Longmen Capital. The proceeds will be used to accelerate the company&#039;s clinical development across multiple indications and to prepare for commercial\u2011scale production.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72188\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T05:41:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T05:41:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01\",\"datePublished\":\"2026-08-10T05:41:28+00:00\",\"dateModified\":\"2026-08-10T05:41:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1005.webp\",\"keywords\":[\"Cell-therapy\",\"Finance\",\"Hopstem Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72188#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72188\",\"name\":\"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1005.webp\",\"datePublished\":\"2026-08-10T05:41:28+00:00\",\"dateModified\":\"2026-08-10T05:41:29+00:00\",\"description\":\"Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million Series C financing round. The round was participated in by new shareholders Tasly Capital, HBVC, and Guangzhou Health Investment, along with existing shareholder Longmen Capital. The proceeds will be used to accelerate the company's clinical development across multiple indications and to prepare for commercial\u2011scale production.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72188\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1005.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72188#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01 - Insight, China&#039;s Pharmaceutical Industry","description":"Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million Series C financing round. The round was participated in by new shareholders Tasly Capital, HBVC, and Guangzhou Health Investment, along with existing shareholder Longmen Capital. The proceeds will be used to accelerate the company's clinical development across multiple indications and to prepare for commercial\u2011scale production.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72188","og_locale":"en_US","og_type":"article","og_title":"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01","og_description":"Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million Series C financing round. The round was participated in by new shareholders Tasly Capital, HBVC, and Guangzhou Health Investment, along with existing shareholder Longmen Capital. The proceeds will be used to accelerate the company's clinical development across multiple indications and to prepare for commercial\u2011scale production.","og_url":"https:\/\/flcube.com\/?p=72188","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T05:41:28+00:00","article_modified_time":"2026-08-10T05:41:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72188#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72188"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01","datePublished":"2026-08-10T05:41:28+00:00","dateModified":"2026-08-10T05:41:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72188"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72188#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1005.webp","keywords":["Cell-therapy","Finance","Hopstem Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72188#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72188","url":"https:\/\/flcube.com\/?p=72188","name":"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72188#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72188#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1005.webp","datePublished":"2026-08-10T05:41:28+00:00","dateModified":"2026-08-10T05:41:29+00:00","description":"Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million Series C financing round. The round was participated in by new shareholders Tasly Capital, HBVC, and Guangzhou Health Investment, along with existing shareholder Longmen Capital. The proceeds will be used to accelerate the company's clinical development across multiple indications and to prepare for commercial\u2011scale production.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72188#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72188"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72188#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1005.webp","width":1080,"height":608,"caption":"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72188#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72188"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72188\/revisions"}],"predecessor-version":[{"id":72191,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72188\/revisions\/72191"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72190"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}